论文部分内容阅读
目的 探讨 mdr- 1、c- erb B- 2和 bcl- 2作为乳腺癌耐药相关基因常规检测的可行性 ,并观察三种基因与肿瘤发展预后的关系 ,以期指导治疗。方法 应用 S- P法免疫组化技术对 43例疗前乳腺癌组织标本的常规切片进行检测。结果 (1 ) c- erb B- 2和 bcl- 2以中高度表达为主 ,mdr- 1则以低表达或无表达为主。 (2 )复发组与未复发组相比 ,mdr- 1表达有显著性差异 (P<0 .0 5 ) ,c-erb B- 2和 bcl- 2则无显著性差异 (P>0 .0 5 )。 (3)复发病例中 c- erb B- 2以高表达为主 ,bcl- 2均为低表达或无表达。结论 三种基因可作为乳腺癌耐药相关基因而用于临床检测并可为术后治疗及判断预后提供依据。
Objective To explore the feasibility of routine detection of mdr-1, c-erb B-2 and bcl-2 as drug-resistance related genes in breast cancer, and to observe the relationship between the three genes and the prognosis of tumor development in order to guide treatment. Methods Immunohistochemical technique of S-P was used to detect the normal sections of 43 pre-treatment breast cancer tissues. Results (1) c-erb B-2 and bcl-2 were mainly expressed at medium and high levels, and mdr-1 was mainly at low or no expression. (2) There was a significant difference in mdr-1 expression between relapsed group and non-relapsed group (P<0.05). There was no significant difference between c-erb B-2 and bcl-2 (P>0. 5). (3) c-erb B-2 was highly expressed in recurrence cases, and bcl-2 was low or no expression. Conclusion The three genes can be used as clinically relevant detection genes for breast cancer resistance and provide evidence for postoperative treatment and prognosis.